Moderate to Severe Plaque PsoriasisPhase 3BE UNIQUENCT06506916
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study testing bimekizumab in people with Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis, run by UCB Biopharma SRL at 14 sites in 3 countries.
Trial summary
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
- What is being tested?
- bimekizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 89 participants
- Where
- 14 sitesin 3 countries
- Study dates
- 29 Jul 2024to 14 Mar 2028
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Cohort A and Cohort B
- Study participant must be at least 18 years of age inclusive at the time of signing the Informed Consent Form (ICF)
- Study participant must have:
- Cohort A and Cohort B: Plaque psoriasis (PSO) diagnosed for at least 6 months prior to the Screening Visit
- Cohort B only: In addition to the criteria specified above, study participant has a documented diagnosis of adult-onset psoriatic arthritis (PsA) and meets the CASPAR classification criteria for at least 6 months prior to Screening for active PsA and must have ≥1 tender joint count (TJC) out of 68 and ≥1 swollen joint count (SJC) out of 66 at Screening or up to 3 months before Screening (documented evidence)
- Study participant must have Psoriasis Area and Severity Index (PASI) score ≥12 and body surface area (BSA) affected by PSO ≥10% and Investigator's Global Assessment (IGA) score ≥3 on a 5 point scale
Show all 16Show fewer
- Study participant must be a candidate for systemic PSO therapy and/or phototherapy
- Study participant agrees not to change their usual sun exposure during the course of the study and to use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs
- Study participant has body weight <120 kg
- A female study participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the Run In Treatment Period, the Randomized Treatment Extension Period, theTreatment Extension Period, the Escape Treatment Period, and for 17 weeks after the final dose of investigational medicinal product (IMP)
- Control Cohort
- Study participant must be ≥18 years of age at the time of signing the informed consent
- Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs
- Study participant has body weight <120 kg
- Female study participant is eligible to participate if they are not pregnant and not breastfeeding
Who cannot join
- Cohort A and Cohort B
- Study participant has a form of PSO other than plaque type (eg, pustular, erythrodermic and guttate PSO, or drug induced PSO)
- Study participant has an active infection or history of infection(s) as follows:
- Any active systemic infection within 14 days prior to Baseline
- A serious infection, defined as requiring hospitalization or intravenous anti-infective(s) within 2 months prior to the Baseline Visit
- A history of opportunistic, recurrent, or chronic infections that, in the opinion of the investigator, might cause this study to be detrimental to the study participant
Show all 20Show fewer
- At investigator's discretion, study participant with chronic (medically controlled) viral hepatitis B or C or human immunodeficiency virus (HIV) infection, or history of hepatitis B.
- Study participant has any of the following:
- Known active tuberculosis (TB) disease.
- History of active TB involving any organ system unless adequately treated
- High risk of acquiring TB infection
- Study participant has a verified diagnosis of inflammatory conditions other than PSO or PsA, including but not limited to rheumatoid arthritis (RA), sarcoidosis, inflammatory bowel diseases (IBD), or systemic lupus erythematosus. Note: Study participants with a diagnosis of IBD are allowed if they have no active symptomatic disease at Screening or Baseline
- Study participant has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
- Study participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study
- Study participant has a known hypersensitivity to any components of the IMP as stated in this protocol
- Study participant has a history of primary failure to any biologic (ie, no response within the first 12 weeks of treatment)
- Study participant has laboratory abnormalities at Screening
- Study participant has a current history of alcohol or drug use disorder, as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM) V, within the previous 6 months prior to Screening, as evaluated by the investigator based on medical history, and/or site interview
- Control Cohort
- Study participant has any systemic disease (eg, cardiovascular, neurological, renal, liver, metabolic, gastrointestinal, hematological, coagulation disorders, immunological) considered by the investigator to be uncontrolled, unstable, or likely to progress to a clinically significant degree during the course of the study
Trial locations and contacts
14 sites in 3 countries.
14 sites in 3 countries
United States6 sites
Ps0039 50110
Ann Arbor, Michigan, 48109
Ps0039 50140
Birmingham, Alabama, 35233
Ps0039 50162
Fountain Valley, California, 92708
Ps0039 50491
Pittsburgh, Pennsylvania, 15213-2536
Ps0039 50643
Rochester, New York, 14623
Ps0039 50283
Tampa, Florida, 33613
Poland5 sites
Ps0039 40347
Lodz
Ps0039 40625
Lodz
Ps0039 40757
Poznan
Ps0039 40761
Warsaw
Ps0039 40773
Wroclaw
Germany3 sites
Ps0039 40515
Berlin
Ps0039 40287
Frankfurt am Main
Ps0039 40072
Freiburg im Breisgau
About this study
Official title: A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
- Being tested
- bimekizumab
- Keywords
- Moderate to Severe Plaque Psoriasis, PSO, Phase 3, Bimekizumab, Biomarkers, PsA
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bimekizumabDrug
Also called BKZ
Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.
| Study group | Role | What they receive |
|---|---|---|
| Cohort A | Experimental | Study participants with moderate to severe plaque PSO without concomitant active PsA (Cohort A) receive bimekizumab dosage regimen 1 from Baseline up to Week 16 and bimekizumab regimen 2 from Week 16 up to Week 48. Study participants, fulfilling randomization criteria receive bimekizumab dosage regimen 2 or 3 from Week 48 to Week 96. Study participants who do not meet the criteria for randomization receive bimekizumab dosage regimen 2 to Week 96. Receives: Drug: bimekizumab |
| Cohort B | Experimental | Study participants with moderate to severe plaque PSO with concomitant active PsA (Cohort B) receive bimekizumab dosage regimen 1 from Baseline up to Week 16 and bimekizumab regimen 2 from Week 16 up to Week 48. Study participants, fulfilling randomization criteria receive bimekizumab dosage regimen 2 or 3 from Week 48 to Week 96. Study participants who do not meet the criteria for randomization receive bimekizumab dosage regimen 2 to Week 96. Receives: Drug: bimekizumab |
| Control Cohort | No intervention | Healthy participants, who will not receive IMP during the study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in composite gene expression score using reverse transcription-polymerase chain reaction (RT-PCR) in lesional skin at Week 48
Composite gene expression score using RT-PCR in lesional skin at Baseline and Week 48 using preselected genes based on bimekizumab mechanism of action and PSO disease biology pathways.
Measured: Week 48, compared to Baseline
Secondary outcomes (3)
Treatment-emergent adverse events (TEAEs) from Baseline to the end of the Safety Follow-Up (SFU)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. TEAEs are defined as those AEs that have a start date on or following the first dose of IMP through SFU (at least 12 weeks after final IMP dose and not before 4 weeks after the last skin biopsy).
Measured: From Baseline to End of SFU (up to Week 100)
Treatment-emergent serious adverse event (TESAEs) from Baseline to the end of the SFU
A serious adverse event (SAE) must meet 1 or more of the following criteria:
- Results in death
- Is life-threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent disability/incapacity
- Is a congenital anomaly/birth defect
- Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious.
TESAEs are defined as those SAEs that have a start date on or following the first dose of IMP through SFU (at least 12 weeks after final IMP dose and not before 4 weeks after the last skin biopsy).
Measured: From Baseline to End of SFU (up to Week 100)
TEAEs leading to permanent discontinuation of IMP from Baseline to the end of the SFU
This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason.
Measured: From Baseline to End of SFU (up to Week 100)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2024
- Study start29 Jul 2024
- Primary completion9 Mar 2027 (estimated)
- Study completion14 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Moderate to Severe Plaque PsoriasisStudies of the same condition, open and under way.
- More trials run by UCB Biopharma SRLThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- UCB Biopharma SRL
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- UCB Cares, Study director, 001 844 599 2273
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06506916
- Sponsor's protocol ID
- PS0039
- Other IDs
- 2023-506333-29-00, U1111-1299-2563, 2023
- Acronym
- BE UNIQUE
- Status last verified
- Jul 2026
- First submitted
- 9 Jul 2024
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.